Article info
PDFOriginal research
Rare diseases in healthcare priority setting: should rarity matter?
- Correspondence to Andreas Albertsen, School of Business and Social Sciences: Department of Political Science, Aarhus University, 8000 Aarhus, Denmark; aba{at}ps.au.dk
Citation
Rare diseases in healthcare priority setting: should rarity matter?
Publication history
- Received October 5, 2020
- Revised April 16, 2021
- Accepted May 4, 2021
- First published June 8, 2021.
Online issue publication
November 16, 2022
Article Versions
- Previous version (16 November 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Should rare diseases get special treatment?
- Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthy life year
- Solidarity, justice and unconditional access to healthcare
- A framework for luck egalitarianism in health and healthcare
- Rare neurological diseases: a practical approach to management
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
- Distributive justice and the harm to medical professionals fighting epidemics
- How the past matters for the future: a luck egalitarian sustainability principle for healthcare resource allocation
- A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
- Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence